Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 3Recruiting 2Active not recruiting 2Withdrawn 1Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Locally Recurrent Skin Squamous Cell Carcinoma 1

Interventions

Specimen Handling 24Biopsy 16Magnetic Resonance Spectroscopy 15Cyclophosphamide 5Bevacizumab 4Vincristine 3Taxes 3Prednisone 3Nivolumab 3Doxorubicin 3Cetuximab 3Azacitidine 3venetoclax 2trastuzumab deruxtecan 2prednylidene 2olaparib 2iadademstat 2deltacortene 2decitabine and cedazuridine drug combination 2X-Rays 2Surgical Procedures, Operative 2Standard of Care 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiation 2Practice Guidelines as Topic 2Paclitaxel 2Ipilimumab 2Immunoglobulin G 2Etoposide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Hyaluronoglucosaminidase × 30 days × Clear all
NCT07042295 2026-06-03

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

National Cancer Institute (NCI)

Phase 2 Suspended
86 enrolled

Locally Recurrent Skin Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡